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low-up and has rehabilitated himself by
performing social work within the prison
walls. This case persuaded me to research
the law and resulted in a publication in the
Journal of Indian Law Institute.2 The sub-
ject was capital punishment and medical
science.
In the case referred to in the editorial, it
appears that medical professionals and le-
gal professionals can come together and
seek an alternative where valuable human
resource is not wasted in the hope of retri-
bution. I am referring to the large number
of prisoners waiting a death sentence in US
prisons. They could be potential organ do-
nors for the community. With the assis-
tance of the medical profession, each pris-
oner who is to be executed can provide
organs for 8 to 10 patients.
This would certainly appeal to society
at large. The article published in the Jour-
nal of Indian Law Institute2 has interested
the law commission in India, which is con-
sidering this suggestion. However, capital
punishment itself is rarely given out in In-
dian courts. Perhaps this thought may be
worth a closer look in your community,
where the number of convicts on death row
is large.
A. Sampath Kumar, MCh
Department of Cardiothoracic/Vascular
Surgery
All India Institute of Medical Sciences
New Delhi, India
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Reply to the Editor:
Readers will be grateful for the informative
letter from Dr Sampath Kumar, who raises
two interesting themes for ethical analysis.
The case that he reports shows how
changes in contextual details can clarify
values and illuminate moral reasoning de-
veloped from analysis of an index case, like
our heart transplant patient. This approach
to ethics is referred to as casuistry. In his
case, the patient was not just in prison but
was on death row, intensifying the apparent
strength of the argument from justice to
withhold treatment because of the serious-
ness of the crime. The treatment was an
expensive valve operation, although it did
not consume as scarce and as valuable a
resource as a donor heart. The principle
that guided his decision was that prisoners
are our fellow citizens and fellow human
beings, to whom physicians have a fidu-
ciary duty to provide care within the
boundaries of resource availability. It is
enriching that he can give us the outcome,
underlining the appropriateness of his de-
cision to apply this principle.
The second theme that he raises is the
issue of allowing prisoners to be organ
donors. The voluntary or involuntary re-
moval of vital organs after execution in
China is an efficient but potentially abusive
solution to the donor shortage. Clifford
Bartz, a federal inmate in Pennsylvania,
described the Inmate Organ Donor Net-
work in the March issue of the Kennedy
Institute of Ethics Journal.1 Bartz and his
colleagues propose that qualified inmates
who pledge up to three organs on their
death should be given 1 year of suspended
prison time, and those who serve as living
donors should receive 7 years of reduced
time. He describes several voluntary dona-
tions of organs from prisoners to their
needy relatives. These are examples of a
form of trade, trading time for organs. In
my Minnesota case of the prisoner who
wanted to collect “rent” for his donated
kidney, described in my reply to Dr Richen-
bacher’s letter,2 this proved to be a Faus-
tian bargain, but this single example should
not lead to a categorical ban. I recommend
a more empirical approach to test the opti-
mistic hypothesis that under the best cir-
cumstances, prisoner organ donation can
be an act of heroism leading to trust and
rehabilitation of a fallen comrade on the
road of life.
We need rewards for donation. As a
blood donor, I favor some advantage
within the health care system for those who
enrich it by donation. This might parallel
the airlines’ policy of rewarding frequent
flyers for their loyalty with expedited
boarding and free air travel on some under-
filled flights. Blood donors, and particu-
larly organ donors, deserve reasonable re-
wards within the health care system, as
long as they do not unfairly disadvantage
other patients. Such a reward system would
strengthen the value assigned by society to
the act or intention to donate.3 Finally, the
use of financial rewards should be explored
as even Veatch,4 a longtime opponent of
this policy, has grouchily come to accept.
The Council on Ethical and Judicial Affairs
of the American Medical Association,
stimulated no doubt by Bob Sade’s pres-
ence on the council, has recommended that
an empirical trial of financial rewards for
organ donors should be conducted to deter-
mine whether it will favorably or unfavor-
ably affect the overall rate of donation or
reduce the donor pool.5
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Bivalirudin as alternative to both
danaparoid and heparin in off-pump
coronary artery bypass grafting
To the Editor:
I enjoyed the recent article “Heparin Ver-
sus Danaparoid in Off-Pump Coronary By-
pass Grafting: Results of a Prospective
Randomized Clinical Trial” by Carrier and
colleagues.1 I favor off-pump coronary ar-
tery bypass grafting in patients with hepa-
rin-induced thrombocytopenia (HIT). Did
Carrier and colleagues1 consider using a
short-acting thrombin inhibitor such as
bivalirudin (Angiomax) rather than danap-
aroid as the heparin alternative?
I have used bivalirudin,2 a short-acting
thrombin inhibitor, in several patients with
Letters to the Editor
2108 The Journal of Thoracic and Cardiovascular Surgery ● December 2003
HIT who have required valve replacement.
Bivalirudin’s half-life of 25 minutes, the
ability to monitor activated clotting time,
and the lack of cross-reactivity with hepa-
rin antibodies were advantages that con-
vinced my group to use it for these patients
with HIT. The patients did well, requiring
an average of 2 units of blood per patient.
My suspicion is that off-pump revascu-
larization with bivalirudin rather than dan-
aparoid would result in lower use of blood
products. It is likely that even on-pump
coronary artery bypass grafting with biva-
lirudin as the anticoagulant will result in
lower blood product use in the HIT cohort.
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Reply to the Editor:
I thank Dr Baciewicz for his comments
regarding our article and thank you for the
opportunity to respond to him. We chose to
compare low dose of the anti-Xa inhibitor
danaparoid with standard heparin in off-
pump coronary artery bypass grafting be-
cause of our significant clinical experience
with the former drug. Although it is not
superior to standard heparin, low-dose dan-
aparoid offers a safe alternative for patients
undergoing off-pump coronary artery by-
pass grafting when heparin is contraindi-
cated.
My group and I have read with interest
the reports on bivalirudin, but we remain
concerned by the limited clinical data
available. In fact, we found only two re-
ports of cardiac surgical patients in the
literature, with one of the patients showing
a large blood drainage through the chest
tubes.1,2
Our current options for patients with
heparin-induced thrombocytopenia are to
use low-dose danaparoid and off-pump
coronary artery bypass grafting or to wait
for disappearance of the antiplatelet anti-
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Apical versus basal partial
ventriculectomy
To the Editor:
With regard to the recent study of Koyama
and colleagues published in the Journal of
Thoracic and Cardiovascular Surgery,1
your readers should be aware that the au-
thors have done no more than confirm the
previous observations of Savage and col-
leagues,2 namely, that reducing volume by
constricting or resecting the apical half of
the ventricular cone has no significant ef-
fect on ventricular pump function. Their
findings also confirm extensive clinical
studies3-6 showing that reduction of the
radius of the ventricle in its upper two
thirds improves pump function, provided
that the ventricle had been markedly di-
lated prior to such an intervention. Thus,
simply by using a figure-of-eight symmet-
rical technique of resection, Konertz and
colleagues5 have achieved results that sur-
pass the current success of cardiac trans-
plantation.
Your readers should also note that the
technique used by the Japanese group to
induce cardiac failure1 produced minimal
alterations in left ventricular function.
Thus, having reduced the radius of the left
ventricle, the diameter in their experimen-
tal study was smaller than under control
conditions. As is well established, how-
ever, any persistent therapeutic effect of
reducing ventricular radius in the clinical
situation is dependent in the degree of pre-
existing ventricular dilation.3-6
Furthermore, due to the beta-blockade
used as part of the experimental setup, the
ensuing bradycardia will have prevented
their hearts from compensating adequately
for the confined stroke volume, as would
have occurred under physiological condi-
tions simply due to an increase in heart
rate. It is irrelevant, therefore, to measure
cardiac output under these experimental
conditions. At all events, stroke volume
increased by one quarter when the radius
was reduced along the basal two thirds of
the heart.
There are then several other problems
with the description and interpretation of
the Japanese group1 that need to be drawn
to the attention of your readers. It is incor-
rect to state that Batista advocated the api-
cal region of the left ventricle as a primary
area for resection. His primary intention
was simply to reduce the radius of the
dilated left ventricle. Furthermore, contrary
to the conclusion drawn by the authors,1
the experimental results show clearly that
plication of the apical segment produces no
positive therapeutic effect. Nor, contrary to
the assertions made by Torrent-Guasp and
his colleagues,7,8 does such plication have
any major detrimental impact on global
ventricular pump function. When consider-
ing the differences observed in left ventric-
ular function after apical or subbasal reduc-
tion of radius in this study, we need to
remember that it is the extensive circular
muscular layer enclosing the upper two
thirds of the left ventricular cone that is
largely responsible for left ventricular ejec-
tion. By reducing its radius, working con-
ditions for the left ventricle are improved,
thus ameliorating its pump function. This
positive effect, however, is mitigated by
plication of the interpapillary segment as
performed by the Japanese investigators, as
this procedure plicates also the marginal
arteries. As has been shown,9 the resulting
ischemic damage extends well beyond the
plicated segment. Indeed, such collateral
damage may well have been more signifi-
cant in those hearts that were plicated up to
the base in the Japanese study as compared
with those plicated only along the apical
half. The positive effect of reducing left
ventricular radius probably would have
been more pronounced had a less traumatic
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